US 11,666,594 B2
Antibody-drug conjugates comprising a cyclic dinucleotide
Masato Yoshikawa, Fujisawa Kanagawa (JP); Morihisa Saitoh, Fujisawa Kanagawa (JP); Taisuke Kato, Fujisawa Kanagawa (JP); Yayoi Nakayama, Fujisawa Kanagawa (JP); Tomohiro Seki, Fujisawa Kanagawa (JP); Yasuo Nakagawa, Fujisawa Kanagawa (JP); Yusuke Tominari, Fujisawa Kanagawa (JP); Masaki Seto, Fujisawa Kanagawa (JP); Yusuke Sasaki, Fujisawa Kanagawa (JP); Masanori Okaniwa, Fujisawa Kanagawa (JP); Tsuneo Oda, Fujisawa Kanagawa (JP); Akito Shibuya, Fujisawa Kanagawa (JP); Kosuke Hidaka, Fujisawa Kanagawa (JP); Zenyu Shiokawa, Fujisawa Kanagawa (JP); Shumpei Murata, Fujisawa Kanagawa (JP); Atsutoshi Okabe, Fujisawa Kanagawa (JP); Yoshihisa Nakada, Fujisawa Kanagawa (JP); Michiyo Mochizuki, Fujisawa Kanagawa (JP); Brian Scott Freeze, Boston, MA (US); Taisuke Tawaraishi, Fujisawa Kanagawa (JP); Yasufumi Wada, Fujisawa Kanagawa (JP); and Paul D. Greenspan, Acton, MA (US)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
Filed on Oct. 7, 2020, as Appl. No. 17/65,242.
Application 17/065,242 is a division of application No. 16/185,258, filed on Nov. 9, 2018, granted, now 10,980,825.
Application 16/185,258 is a continuation of application No. PCT/IB2017/057588, filed on Dec. 1, 2017.
Claims priority of provisional application 62/589,300, filed on Nov. 21, 2017.
Claims priority of application No. 2016-234553 (JP), filed on Dec. 1, 2016; and application No. 2017-107216 (JP), filed on May 30, 2017.
Prior Publication US 2021/0106607 A1, Apr. 15, 2021
Int. Cl. A61K 31/7084 (2006.01); A61P 35/00 (2006.01); C07H 21/00 (2006.01); C07H 21/02 (2006.01); A61K 47/68 (2017.01); A61K 31/7076 (2006.01)
CPC A61K 31/7084 (2013.01) [A61K 31/7076 (2013.01); A61K 47/6807 (2017.08); A61P 35/00 (2018.01); C07H 21/00 (2013.01); C07H 21/02 (2013.01)] 19 Claims
 
1. A compound having Formula (XIV):
(CD-L)n-A  (XIV)
or a pharmaceutically acceptable salt thereof, wherein:
CD is a group selected from any one of Formulae (XX), (XXIV), (XXVIII), or (XXIX):

OG Complex Work Unit Chemistry
R1 and R2 are each independently a hydroxy group, hydrogen, amino group, or a halogen atom;
B3 and B4 are independently an optionally substituted 5- to 14-membered aromatic heterocyclic group;
X1 and X2 are each an oxygen atom;
Q1, Q2, Q3, and Q4 are each independently an oxygen atom or a sulfur atom;
L is a linker;
A is an antibody or antibody fragment; and
n is 1-10.